knowledge -WSS

knowledge

author：knowledge 2025-09-27 22:48:26 - browse：8418

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： How the BIOSECURE Act is already affecting U.S., Chinese life science firms

WSS

Cigna wins case to block Amy Bricker's move to CVS

5 takeaways from STAT's examination of Zynex Medical

5 takeaways from STAT's examination of Zynex Medical

NIH director takes cautious approach to Biden drug pricing priority

Health care court cases: Humana, Sutter, Novant

Teladoc has a new CEO, but challenges remain the same

focus

knowledge

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Supreme Court strikes down use of affirmative action

Dewpoint Therapeutics lays off staff after losing partnerships

Affirmative action in medical school literally saved lives

Cheap, fast test for Zika and dengue could cost just $1

At least 13 dead in Texas as scorching temps continue

The system is set up to fail children with medical complexity

Medical leaders decry Supreme Court decision on affirmative action

Medical device trials still don't enroll enough women, study finds

knowledge

Coercive sterilizations revealed by STAT prompt outrage

Prior authorization will have to move faster under new Biden rule

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Cheap, fast test for Zika and dengue could cost just $1

Copay coupons to count toward deductibles, after Biden court move

5 takeaways from STAT's examination of Zynex Medical

hotspot

focus

leisure time

Wikipedia